Targacept reports $12.9M loss in third quarter - Winston-Salem Journal: Business News

Sunday, May 1st, 2016

Targacept reports $12.9M loss in third quarter

Print
Font Size:
Default font size
Larger font size

Posted: Tuesday, November 5, 2013 10:12 am

Higher research and development expenses contributed to a larger loss for Targacept Inc. in the third quarter, the Winston-Salem biotechnology company reported Tuesday.

Targacept develops drugs based on the use of nicotinic receptors to treat diseases, with a primary focus on the central nervous system. It has served as an anchor of the Triad’s biotechnology sector for several years.

Subscription Required

An online service is needed to view this article in its entirety. You need an online service to view this article in its entirety.

Have an online subscription?

Login Now

Need an online subscription?

Subscribe

Login

Choose an online service.

The following services are print only and offer no digital access

You must login to view the full content on this page.

Thank you for reading 12 free articles on our site. You can come back at the end of your 30-day period for another 12 free articles, or you can purchase a subscription and continue to enjoy valuable local news and information. If you need help, please contact our office at 336-727-7211. You need an online service to view this article in its entirety.

Have an online subscription?

Login Now

Need an online subscription?

Subscribe

Login

Choose an online service.

The following services are print only and offer no digital access

More about

loading...
  • ABC NC-CHILDREN DEV. CTR.

    • icon Updated: 12:09 am
More Print Ads